3 completed, 1 no longer available, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow TFF Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients Tacrolimus Inhalation Powder, Plastiape RS00 Dry Powder inhaler device - Lung Transplant Rejection | Phase 2 | Terminated | TFF Pharmaceuticals, Inc. | 14 | 2023-04-18 | 2025-01-06 |
| Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects Niclosamide Inhalation Powder, Placebo - Healthy | Phase 1 | Completed | TFF Pharmaceuticals, Inc. | 40 | 2021-11-14 | 2022-02-02 |
| Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma Voriconazole Inhalation Powder, Placebo - Asthma | Phase 1 | Completed | TFF Pharmaceuticals, Inc. | 17 | 2020-11-15 | 2021-11-18 |
| Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects Voriconazole Inhalation Powder, Placebo - Healthy | Phase 1 | Completed | TFF Pharmaceuticals, Inc. | 65 | 2019-11-22 | 2021-05-06 |
| Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis Voriconazole Inhalation Powder - Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis | No longer available | TFF Pharmaceuticals, Inc. | 2024-11-21 |
Pulmonary Aspergillosis (3) · Aspergillosis (2) · Mycoses (2) · Respiratory Aspiration (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Asthma (1) · Invasive Pulmonary Aspergillosis (1) · Lung Diseases, Fungal (1)
Tacrolimus (1)
Australia (2) · Canada (2)
Dale Christensen, PhD (3) · Zamaneh Mikhak, MD (1)